A CAR-T Success Story in China: A Beacon of Hope for Acute Myeloid Leukemia(AML) Patients #CAR-T #AcuteMyeloidLeukemia #AML #ChinaHealthcare #patientstory #CD33 In the field of cancer treatment, China’s medical advancements have brought new therapeutic opportunities for patients, especially with CAR-T cell therapy. Although CAR-T has achieved significant success in treating lymphoid tumors, its application in myeloid malignancies, particularly acute Read More
Leukemia
**Nature Medicine | New Breakthrough in China’s CAR-T Therapy: Significant Progress in Allogeneic CD5 CAR-T Treatment for Relapsed T-ALL** #CAR-TTherapy #TALL #ALL #Leukemia #RelapsedLeukemia #TCellLeukemia #CD5 #CD7 #CART Recently, a collaborative research study conducted by multiple Chinese medical and research institutions was published in *Nature Medicine*. This study, titled “Allogeneic CD5-specific CAR-T Therapy for Relapsed/Refractory T-ALL: A Phase 1 Read More
**Real-World Performance of China’s Anti-Cancer Drug Zanubrutinib in CLL/SLL Treatment: Efficacy and Safety** #Ibrutinib #Zanubrutinib #CLL #SLL #BTKinhibitor #Oncology #cancerdrug #BTK #ASCO With the advent of BTK inhibitors, the treatment paradigm for chronic lymphocytic leukemia (CLL) and small lymphocytic lymphoma (SLL) has undergone a complete transformation, moving away from traditional chemotherapy. Zanubrutinib, a powerful BTK inhibitor developed independently Read More
Nature Communications | Chinese Medical Team Innovates CAR-T Therapy to Bring New Hope for AML Treatment In the field of hematological malignancies, the treatment of acute myeloid leukemia (AML) has long been a challenge in the medical community. Particularly for relapsed or refractory patients, the limitations of traditional treatments have increased the urgent need for Read More
### Chinese Hospital’s CAR-T Therapy Saves the Life of a Ph+ Acute Lymphoblastic Leukemia Patient | Successful Case from The First Affiliated Hospital of Chongqing Medical University On November 7, 2023, China’s first CAR-T product for treating adult leukemia, Yuan Ruida (Inaticabtagene Autoleucel Injection), was officially approved for market release. This marks a significant breakthrough Read More
The new hope for pediatric patients with relapsed/refractory B-cell acute lymphoblastic leukemia (R/R B-ALL) boasts an overall survival rate of up to 96%. Recently, CAR-T cell therapy targeting B-cell malignancies has encountered a series of inquiries and challenges, particularly concerning discussions on CAR-T cell-related toxicity, resistance, antigen escape, and limitations in persistence. However, Read More
In recent years, CAR-T therapy has gained traction in treating leukemia. A quick search yields numerous articles, many of which describe the miraculous effects of CAR-T. Is the efficacy of CAR-T therapy really that impressive? Should CAR-T therapy be considered for a child diagnosed with leukemia? Today, let’s unravel these doubts together! What kind of Read More